Clinical Trials Logo

Clinical Trial Summary

Malaria is the most important human parasitic disease and is responsible of high morbidity and mortality in resource-poor countries. Pregnant women, who are a high-risk group, are almost always excluded from clinical trials; thus, the investigators lack sufficient information on the safety and efficacy of most antimalarials in pregnancy. The recommendation of the World Health Organization to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries, however documentation of their efficacy and safety in pregnancy is still limited. Thus, the investigators propose to evaluate the efficacy and safety of 4 ACT(artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), when used to treat pregnant women with P. falciparum malaria; the results will help to recommend the optimal therapy for this high-risk group in Africa.


Clinical Trial Description

Malaria is the most important human parasitic disease. Although pregnant women are a high-risk group, they are almost systematically excluded from clinical trials, for fear of teratogenicity and embryotoxicity; thus, we generally lack sufficient information on the safety and efficacy of most antimalarials in pregnancy, as well as evidence-based recommendations for the prevention and treatment of malaria during pregnancy.

The WHO recommendation to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries. However, the documentation of their efficacy and safety in pregnancy is still limited, especially concerning the African contexts.

Therefore, we propose to test 4 fixed-dose combinations (artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), to evaluate their efficacy and safety when administered to pregnant women (2nd and 3rd trimester) infected with P. falciparum. Explanatory variables will be collected for treatment failure (PCR-corrected) and for recurrent parasitaemia. The primary hypothesis tested will be the clinical equivalence (pair-wise non-inferiority) of the 4 treatment regimens with clinical equivalence defined as difference in treatment failure rates (PCR corrected) of 5% or less.

In addition, an attempt will be done to carry out in vitro testing at the time of recurrent infection. However, the success of the test will depend on the parasite density. In addition, blood samples collected on filter paper at day 0 and at day of recurrent parasitaemia will be genotyped for the search of known molecular markers related to drug resistance. Not all samples will be analyzed; rather these will be selected according to the therapeutic response so that the prevalence of molecular markers will be compared between treatment successes, true treatment failures and new infections. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00852423
Study type Interventional
Source Institute of Tropical Medicine, Belgium
Contact
Status Completed
Phase Phase 3
Start date June 2010
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT03508349 - Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda N/A
Completed NCT01053325 - Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy Phase 3
Completed NCT00140517 - Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance N/A
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Active, not recruiting NCT01555255 - Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria N/A
Completed NCT01136850 - Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea Phase 3
Terminated NCT04148690 - Assessing the Impact of Group Antenatal Care on IPTp Uptake in Tanzania N/A
Completed NCT04160026 - Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya Phase 4
Completed NCT04783051 - Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) Phase 3
Not yet recruiting NCT05348746 - ERASE - Impact of COVID-19 on Malaria Control
Completed NCT03998839 - TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
Completed NCT03208179 - Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa Phase 3
Completed NCT01120145 - Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi N/A
Completed NCT00730366 - New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa Phase 3
Completed NCT00680732 - Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Phase 4
Recruiting NCT03754322 - LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial N/A
Not yet recruiting NCT03944317 - Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP) N/A
Completed NCT05294406 - Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia Phase 4
Recruiting NCT04825782 - MiMBa Pregnancy Registry